Trials / Completed
CompletedNCT00062478
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- BioNumerik Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Karenitecin (BNP1350) | Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity. |
Timeline
- Start date
- 2001-10-01
- Primary completion
- 2002-08-01
- First posted
- 2003-06-12
- Last updated
- 2020-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00062478. Inclusion in this directory is not an endorsement.